Gleevec

Type: Product
Name: Gleevec
First reported 14 hours ago - Updated 14 hours ago - 1 reports

Novartis Japan Unit Failed To Notify Ministry Of 2,579 Serious Side Effects

Article # 28140901001Posted: Aug. 31, 2014 10:40 PM GMTExecutive SummaryNovartis Pharma K.K. disclosed that it failed to report as required 2,579 serious side effects cases for several of its drugs in Japan, 1,313 of them related to its Glivec (imatinib) ... [Published Health News Daily - 14 hours ago]
First reported Aug 31 2014 - Updated Aug 31 2014 - 1 reports

Action needed

Several years ago, I was diagnosed with Chronic Myelogenous Leukemia (CML). At one time, the only cure for this type of leukemia was a complete bone marrow transplant. Thanks to research, over the past decade new oral chemotherapy drugs have been approved ... [Published Sun Gazette - Aug 31 2014]
First reported Aug 30 2014 - Updated Aug 30 2014 - 3 reports

Novartis fails to report side effects, fatality

6:52 pm, August 30, 2014 Jiji PressNovartis Pharma K.K. said it has failed to report to the health ministry at least 2,579 cases of serious side effects, including a fatality, from its drugs for leukemia and other diseases even though its employees ... [Published PharmaGossip - Aug 30 2014]
First reported Aug 27 2014 - Updated Aug 27 2014 - 1 reports

Most-costly ACA plans cheapest for specialty drug patients

By 3:45 pm, Aug. 27 |Individuals with chronic diseases such as multiple sclerosis or cancer will likely spend far less money if they enroll in platinum plans through the exchanges, even though those typically have the highest monthly premiums, according ... [Published Modern Healthcare - Aug 27 2014]
First reported Aug 27 2014 - Updated Aug 27 2014 - 1 reports

REVISED NORMS FOR ISSUE OF PATENTS

The Section 3(d) of the amended Indian Patent Act of 2005 is a key safeguard against ever greening of a drug patent by the inventor companies by making some incremental changes to the original molecule. This section is specifically included in the Patent ... [Published PharmaBiz - Aug 27 2014]
Entities: Patent, Molecule, Caduet
First reported Aug 21 2014 - Updated Aug 21 2014 - 1 reports

Puma Biotechnology: Who Are They? What Happened? And, Where Are They Going?

Summary The ExteNET announcement was confusing to many, however, the stock price still sky rocketed. My interpretation of the announcement gives a 3 year disease free survival of ~90% vs. ~85% with Herceptin alone. At current levels, PBYI is a SEL ... [Published Seeking Alpha - Aug 21 2014]
First reported Aug 21 2014 - Updated Aug 21 2014 - 1 reports

Locals raising money for leukemia prior to Lake Tahoe Marathon

INCLINE VILLAGE, Nev. — Warren Kendall remembers pretty vividly when, where and how he heard the news.It was at the end of his fall semester at the University of Miami (Ohio), and at 3:30 p.m. Dec. 18, 2008, he got the phone call.“The doctor told me my ... [Published Tahoe Daily Tribune - Aug 21 2014]
First reported Aug 19 2014 - Updated Aug 19 2014 - 2 reports

Pharma Patent Ruling Pinches Opportunities in Emerging Markets

The decision by an Indian court not to grant a new patent to drug firm Novartis for a modified form of its cancer drug Glivec (known as Gleevec in the U.S.) was a heavy blow to the company. It may be more than that, though, as other pharmaceutical companies ... [Published AdvisorOne - Aug 19 2014]
First reported Aug 10 2014 - Updated Aug 10 2014 - 1 reports

Change rules to help cancer patients

Posted:Sunday, August 10, 2014, 1:08 AMKathy Hawkinsis a writer in CarlisleSeveral years ago, I was diagnosed with chronic myelogenous leukemia (CML). At one time, the only cure for this type of leukemia was a complete bone marrow transplant. Thanks to ... [Published Philadelphia Inquirer - Aug 10 2014]
First reported Aug 08 2014 - Updated Aug 08 2014 - 1 reports

Even At $900 (Vs. $84,000 In US) Hep C Cure Sovaldi's Cost Could Be Unacceptable In India

US payers and lawmakers have criticized Gilead Sciences' pricing of the new hepatitis C drug Sovaldi, which sells for $84 000 in the country for a 12-week course, notably because the therapy costs less in the rest of the world, reported Forbes. In Europe, ... [Published FirstWord Pharma - Aug 08 2014]
First reported Aug 08 2014 - Updated Aug 08 2014 - 1 reports

Oral Oncolytics Series: Leukemia, 2014 - 2024

Research and Markets (http://www.researchandmarkets.com/research/kth7kb/oral_oncolytics) has announced the addition of the "" report to their offering. Targeted therapeutics is fast emerging as the key focus area in biopharmaceutical industry. Oral targeted ... [Published Individual.com - Aug 08 2014]
First reported Aug 06 2014 - Updated Aug 06 2014 - 1 reports

The anti-cancer drugs market will generate $122.3bn in 2018, a new study predicts

vg - Aug. 6, 2014 - LONDON, U.K. -- A new report by visiongain forecasts the world cancer treating drugs market will achieve revenues of $122.3 billion in 2018. That revenue prediction and others appear in Anti-Cancer Drugs Industry and Market: Therapies, ... [Published Prlog - Aug 06 2014]

Quotes

"FIG. 9 shows the cumulative survival of mice injected with human multiple myeloma cells and treated with Compound 5 of Group I, as compared to control mice not treated with Compound 5."

More Content

All (124) | News (94) | Reports (0) | Blogs (30) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Novartis Japan Unit Failed To Notify Ministry O... [Published Health News Daily - 14 hours ago]
Action needed [Published Sun Gazette - Aug 31 2014]
Novartis fails to report side effects, fatality [Published PharmaGossip - Aug 30 2014]
Novartis fails to report side effects, fatality [Published The Japan News - Aug 30 2014]
Novartis Pharma fails to report over 2,500 seri... [Published Japan Times - Aug 30 2014]
Artificial intelligence, big data and harnessin... [Published MedCity News - Aug 29 2014]
Berg and the Pursuit of the Body's Hidden Drugs [Published Bio-IT World - Aug 28 2014]
Patent Application Titled "Methods of Treating ... [Published 4 Traders - Aug 28 2014]
Most-costly ACA plans cheapest for specialty dr... [Published Modern Healthcare - Aug 27 2014]
REVISED NORMS FOR ISSUE OF PATENTS [Published PharmaBiz - Aug 27 2014]
Column: Relay for Life funds have many benefits [Published Worthington Daily Globe - Aug 26 2014]
Sunitinib: First Drug Active in Refractory Meni... [Published Diabetes Care - Aug 22 2014]
Puma Biotechnology: Who Are They? What Happened... [Published Seeking Alpha - Aug 21 2014]
Locals raising money for leukemia prior to Lake... [Published Tahoe Daily Tribune - Aug 21 2014]
Novartis to start production of Tasigna in Russia [Published Pharma Letter - Aug 20 2014]
Pharma Patent Ruling Pinches Opportunities in E... [Published AdvisorOne - Aug 19 2014]
Drug cos’ biz plans upset after court injunction [Published Economic Times - Aug 19 2014]
Improving the FDA, Ctd [Published Atlantic Monthly - Aug 16 2014]
Improving the FDA, Ctd [Published The Daily Dish | By Andrew Sullivan - Aug 16 2014]
The Cancer Industry is Too Prosperous to Allow ... [Published Health Impact News - Aug 15 2014]
Oncology Research Digest H1 2014 [Published MyNewsDesk - Aug 14 2014]
No new treatments for gastrointestinal stromal ... [Published Orthopedics Today - Aug 13 2014]
Research Leader Looks Beyond Genetic Mechanisms... [Published OncLive - Aug 12 2014]
Survey: Imatinib and Sunitinib Will Continue to... [Published PT Community - Aug 12 2014]
Putting Your Specialty Pharmacy to Work for You [Published OncoLink - Aug 12 2014]
Calling on Cancer's A-Team [Published Yahoo! News - Aug 11 2014]
For trees and heritage [Published Philippine Daily Inquirer - Aug 10 2014]
Change rules to help cancer patients [Published Philadelphia Inquirer - Aug 10 2014]
Even At $900 (Vs. $84,000 In US) Hep C Cure Sov... [Published FirstWord Pharma - Aug 08 2014]
Even At $900 Per Cure, Sovaldi's Cost Could Be ... [Published Forbes.com - Aug 08 2014]
1 2 3 4 5
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Novartis fails to report side effects, fatality [Published PharmaGossip - Aug 30 2014]
6:52 pm, August 30, 2014 Jiji PressNovartis Pharma K.K. said it has failed to report to the health ministry at least 2,579 cases of serious side effects, including a fatality, from its drugs for leukemia and other diseases even though its employees ...
Improving the FDA, Ctd [Published The Daily Dish | By Andrew Sullivan - Aug 16 2014]
by Elizabeth Nolan Brown Should the U.S. Food and Drug Administration inch closer to Europe’s drug approval model , in which certified, independent bodies can (and compete to) review new products? A Dish reader says, hey, it worked for the Federal ...
Human medicines European public assessment repo... [Published Pending EC decisions and European Public Assess ... - Aug 05 2014]
Phenotypic Assays in Cancer Drug Discovery [Published In the Pipeline - Jul 24 2014]
The topic of phenotypic screening has come up around here many times, as indeed it comes up very often in drug discovery. Give your compounds to cells or to animals and look for the effect you want: what could be simpler? Well, a lot of things could, ...
The High Cost of Second-Generation TKIs for CML... [Published PR Newswire: General Business - Jul 15 2014]
BURLINGTON, Mass., July 15, 2014 /PRNewswire/ -- Decision Resources Group finds that, despite the fact that the treatment armamentarium for chronic myeloid leukemia (CML) in Brazil and Mexico includes all three tyrosine kinase inhibitors (TKIs)—Novartis' ...
1 2 3 4 5 6
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.